PF-06952229 是 TGFβRI 的选择性抑制剂。 PF-06952229 可用于治疗实体瘤,特别是转移性乳腺癌的研究。
产品描述
PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer.
体内活性
In MCF-7 ER+ HER2-xenograft breast cancer tumor model, PF-06952229 (30 mg/kg; gavage) combines with Palbociclib results in an improved inhibition of pSMAD2 and a significant increase in survival[1].
Cas No.
1801333-55-0
分子式
C23H24ClFN4O3
分子量
458.91
别名
PF06952229
储存和溶解度
DMSO:40 mg/mL (87.2 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years